Cogent Biosciences Net Income
| COGT Stock | USD 37.20 0.57 1.51% |
As of the 12th of February 2026, Cogent Biosciences shows the Risk Adjusted Performance of 0.1191, mean deviation of 4.71, and Downside Deviation of 2.58. Cogent Biosciences technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Cogent Biosciences Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 925.407 | Earnings Share (2.05) | Quarterly Revenue Growth (1.00) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -230.3 M | -218.8 M | |
| Net Loss | -230.3 M | -218.8 M | |
| Net Loss | -126.2 M | -132.5 M | |
| Net Loss | (2.22) | (2.33) | |
| Net Income Per E B T | 0.86 | 0.76 |
Cogent | Net Income | Build AI portfolio with Cogent Stock |
The evolution of Net Income for Cogent Biosciences provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Cogent Biosciences compares to historical norms and industry peers.
Latest Cogent Biosciences' Net Income Growth Pattern
Below is the plot of the Net Income of Cogent Biosciences over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Cogent Biosciences financial statement analysis. It represents the amount of money remaining after all of Cogent Biosciences operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Cogent Biosciences' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cogent Biosciences' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (255.86 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Cogent Net Income Regression Statistics
| Arithmetic Mean | (77,941,091) | |
| Coefficient Of Variation | (116.47) | |
| Mean Deviation | 75,322,246 | |
| Median | (30,273,000) | |
| Standard Deviation | 90,780,212 | |
| Sample Variance | 8241T | |
| Range | 249.3M | |
| R-Value | (0.89) | |
| Mean Square Error | 1871.6T | |
| R-Squared | 0.79 | |
| Slope | (15,949,008) | |
| Total Sum of Squares | 131856.7T |
Cogent Net Income History
Other Fundumenentals of Cogent Biosciences
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Cogent Biosciences Net Income component correlations
Cogent Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Cogent Biosciences is extremely important. It helps to project a fair market value of Cogent Stock properly, considering its historical fundamentals such as Net Income. Since Cogent Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cogent Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cogent Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Biotechnology market expansion? Will Cogent introduce new products? Factors like these will boost the valuation of Cogent Biosciences. Projected growth potential of Cogent fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Cogent Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Investors evaluate Cogent Biosciences using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Cogent Biosciences' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause Cogent Biosciences' market price to deviate significantly from intrinsic value.
It's important to distinguish between Cogent Biosciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cogent Biosciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Cogent Biosciences' market price signifies the transaction level at which participants voluntarily complete trades.
Cogent Biosciences 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Cogent Biosciences' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Cogent Biosciences.
| 11/14/2025 |
| 02/12/2026 |
If you would invest 0.00 in Cogent Biosciences on November 14, 2025 and sell it all today you would earn a total of 0.00 from holding Cogent Biosciences or generate 0.0% return on investment in Cogent Biosciences over 90 days. Cogent Biosciences is related to or competes with Arcus Biosciences, Immunitybio, Denali Therapeutics, Galapagos, Liquidia Technologies, Ocular Therapeutix, and Agios Pharm. Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined dis... More
Cogent Biosciences Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Cogent Biosciences' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Cogent Biosciences upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.58 | |||
| Information Ratio | 0.1314 | |||
| Maximum Drawdown | 126.24 | |||
| Value At Risk | (4.39) | |||
| Potential Upside | 5.71 |
Cogent Biosciences Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cogent Biosciences' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Cogent Biosciences' standard deviation. In reality, there are many statistical measures that can use Cogent Biosciences historical prices to predict the future Cogent Biosciences' volatility.| Risk Adjusted Performance | 0.1191 | |||
| Jensen Alpha | 1.75 | |||
| Total Risk Alpha | 0.2961 | |||
| Sortino Ratio | 0.7598 | |||
| Treynor Ratio | 0.6203 |
Cogent Biosciences February 12, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1191 | |||
| Market Risk Adjusted Performance | 0.6303 | |||
| Mean Deviation | 4.71 | |||
| Semi Deviation | 1.8 | |||
| Downside Deviation | 2.58 | |||
| Coefficient Of Variation | 722.83 | |||
| Standard Deviation | 14.93 | |||
| Variance | 222.76 | |||
| Information Ratio | 0.1314 | |||
| Jensen Alpha | 1.75 | |||
| Total Risk Alpha | 0.2961 | |||
| Sortino Ratio | 0.7598 | |||
| Treynor Ratio | 0.6203 | |||
| Maximum Drawdown | 126.24 | |||
| Value At Risk | (4.39) | |||
| Potential Upside | 5.71 | |||
| Downside Variance | 6.66 | |||
| Semi Variance | 3.24 | |||
| Expected Short fall | (7.13) | |||
| Skewness | 7.62 | |||
| Kurtosis | 60.5 |
Cogent Biosciences Backtested Returns
Cogent Biosciences appears to be very steady, given 3 months investment horizon. Cogent Biosciences secures Sharpe Ratio (or Efficiency) of 0.0722, which signifies that the company had a 0.0722 % return per unit of risk over the last 3 months. We have found twenty-eight technical indicators for Cogent Biosciences, which you can use to evaluate the volatility of the firm. Please makes use of Cogent Biosciences' Downside Deviation of 2.58, risk adjusted performance of 0.1191, and Mean Deviation of 4.71 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Cogent Biosciences holds a performance score of 5. The firm shows a Beta (market volatility) of 3.31, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Cogent Biosciences will likely underperform. Please check Cogent Biosciences' value at risk, and the relationship between the jensen alpha and skewness , to make a quick decision on whether Cogent Biosciences' price patterns will revert.
Auto-correlation | 0.28 |
Poor predictability
Cogent Biosciences has poor predictability. Overlapping area represents the amount of predictability between Cogent Biosciences time series from 14th of November 2025 to 29th of December 2025 and 29th of December 2025 to 12th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Cogent Biosciences price movement. The serial correlation of 0.28 indicates that nearly 28.0% of current Cogent Biosciences price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.28 | |
| Spearman Rank Test | 0.11 | |
| Residual Average | 0.0 | |
| Price Variance | 2.57 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Cogent Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Cogent Biosciences reported net income of (255.86 Million). This is 174.97% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 144.81% higher than that of the company.
Cogent Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cogent Biosciences' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cogent Biosciences could also be used in its relative valuation, which is a method of valuing Cogent Biosciences by comparing valuation metrics of similar companies.Cogent Biosciences is currently under evaluation in net income category among its peers.
Cogent Biosciences Current Valuation Drivers
We derive many important indicators used in calculating different scores of Cogent Biosciences from analyzing Cogent Biosciences' financial statements. These drivers represent accounts that assess Cogent Biosciences' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Cogent Biosciences' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 124.4M | 332.3M | 679.0M | 810.1M | 729.1M | 765.5M | |
| Enterprise Value | (112.5M) | 115.8M | 558.8M | 729.4M | 656.4M | 689.3M |
Cogent Biosciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Cogent Biosciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Cogent Biosciences' managers, analysts, and investors.Environmental | Governance | Social |
Cogent Biosciences Institutional Holders
Institutional Holdings refers to the ownership stake in Cogent Biosciences that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Cogent Biosciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Cogent Biosciences' value.| Shares | Vestal Point Capital Lp | 2025-06-30 | 3.1 M | Hhg Plc | 2025-06-30 | 2.9 M | Octagon Capital Advisors Lp | 2025-06-30 | 2.8 M | Geode Capital Management, Llc | 2025-06-30 | 2.7 M | Deerfield Management Co | 2025-06-30 | 2.6 M | Sofinnova Ventures | 2025-06-30 | 2.4 M | Commodore Capital Lp | 2025-06-30 | 2.3 M | Saturn V Capital Management Llc | 2025-06-30 | 2.3 M | Nantahala Capital Management, Llc | 2025-06-30 | 1.7 M | Fmr Inc | 2025-06-30 | 17.1 M | Paradigm Biocapital Advisors Lp | 2025-06-30 | 10.4 M |
Cogent Fundamentals
| Return On Equity | -0.95 | ||||
| Return On Asset | -0.47 | ||||
| Current Valuation | 5.58 B | ||||
| Shares Outstanding | 153.51 M | ||||
| Shares Owned By Insiders | 0.28 % | ||||
| Shares Owned By Institutions | 94.40 % | ||||
| Number Of Shares Shorted | 16.92 M | ||||
| Price To Earning | (5.03) X | ||||
| Price To Book | 29.97 X | ||||
| Price To Sales | 1,321 X | ||||
| Gross Profit | (121.63 M) | ||||
| EBITDA | (271.59 M) | ||||
| Net Income | (255.86 M) | ||||
| Cash And Equivalents | 325.56 M | ||||
| Cash Per Share | 4.95 X | ||||
| Total Debt | 17.47 M | ||||
| Debt To Equity | 0.09 % | ||||
| Current Ratio | 11.96 X | ||||
| Book Value Per Share | 1.39 X | ||||
| Cash Flow From Operations | (207.79 M) | ||||
| Short Ratio | 6.84 X | ||||
| Earnings Per Share | (2.05) X | ||||
| Price To Earnings To Growth | (0.14) X | ||||
| Target Price | 52.58 | ||||
| Number Of Employees | 205 | ||||
| Beta | 0.47 | ||||
| Market Capitalization | 5.8 B | ||||
| Total Asset | 327.9 M | ||||
| Retained Earnings | (859.48 M) | ||||
| Working Capital | 240.76 M | ||||
| Current Asset | 37.62 M | ||||
| Current Liabilities | 21.06 M | ||||
| Net Asset | 327.9 M |
About Cogent Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cogent Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cogent Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cogent Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Cogent Stock Analysis
When running Cogent Biosciences' price analysis, check to measure Cogent Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cogent Biosciences is operating at the current time. Most of Cogent Biosciences' value examination focuses on studying past and present price action to predict the probability of Cogent Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cogent Biosciences' price. Additionally, you may evaluate how the addition of Cogent Biosciences to your portfolios can decrease your overall portfolio volatility.